Hématomes maculaires après injections intravitréennes d’anti-VEGF pour dégénérescence maculaire liée à l’âge : série rétrospective

Baeteman, C.; Hoffart, L.; Galland, F; Ridings, B.; Conrath, J.

doi:10.1016/j.jfo.2009.04.001

Cited by 15 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Goverdhan and Lochhead1 has described four cases of submacular hemorrhage after intravitreal bevacizumab all occurring in large neovascular lesions and the same finding was described by Baeteman et al reporting six cases of submacular hemorrhage after ranibizumab injection 23. In these series the hemorrhages developed at a median of 14 to 25 days after the anti-VEGF injection, while in our cases the median was 2.6 days.…”

Section: Discussionsupporting

confidence: 83%

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD

Tognetto¹,

Skiadaresi²,

Cecchini³

et al. 2011

OPTH

View full text Add to dashboard Cite

We describe three cases of submacular hemorrhage that occurred two to four days after anti-VEGF intravitreal injection for occult choroidal neovascularisation in age-related macular degeneration and their management with 25 gauge pars plana vitrectomy with injection of subretinal recombinant tissue plasminogen activator (rTPA) followed by fluid-air exchange and postoperative prone position. Vitrectomy, subretinal rTPA injection and fluid-gas exchange apply as a safe and effective treatment in these cases. Functional results seem to be positive especially if surgical treatment is promptly performed.

show abstract

Section: Discussionsupporting

confidence: 83%

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD

Tognetto¹,

Skiadaresi²,

Cecchini³

et al. 2011

OPTH

View full text Add to dashboard Cite

show abstract

“…However, some studies have shown a higher risk for subretinal hemorrhages after an anti-VEGF IVI in a number of ocular conditions. [25][26][27][28] Anti-VEGF IVI can increase the risk for pigment epithelial tears and detachment, leading to hemorrhages underneath the retinal epithelium. However, other studies have used anti-VEGF agents as an adjuvant treatment of subretinal hemorrhage.…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes of Retinal Arterial Macroaneurysms With Vitreous Hemorrhage Treated With Observation, Antivascular Endothelial Growth Factor Intravitreal Injections, or Pars Plana Vitrectomy

Lam,

Shahlaee,

Salabati

et al. 2023

Journal of VitreoRetinal Diseases

View full text Add to dashboard Cite

Purpose: To evaluate the clinical outcomes of different types of treatment of retinal arterial macroaneurysm with vitreous hemorrhage. Methods: This retrospective cohort study comprised patients with retinal arterial macroaneurysm and vitreous hemorrhage who were examined at a single retina clinic between 2013 and 2021. Results: Treatment arms included observation (n = 33), intravitreal injections (IVI) of antivascular endothelial growth factor agents (n = 5), and pars plana vitrectomy (PPV; n = 12). Baseline characteristics and final best-corrected visual acuity (BCVA) were similar in a combined analysis of all treatment groups ( P > .05). BCVA improved in all eyes, but the IVI and PPV arms had worse presenting BCVA. The mean number of injections was 3.6 ± 2.8. The incidence of subretinal hemorrhage was 18.2% in the observation arm, 25.0% in the PPV group (8.3% had subretinal tissue plasminogen activator), and 60.0% in the IVI group. The mean time to intervention was 13 ± 15.3 days for PPV and 38 ± 69.9 days for IVI. There was no correlation between the number of injections and final BCVA ( r = 0.13, P = .830). The IVI and PPV arms were more frequently on anticoagulants ( P = .011). There was no difference in final BCVA between those using anticoagulants (0.52 ± 0.53) vs not using anticoagulants (0.55 ± 0.65; P = .870). Conclusions: Most patients, regardless of treatment modality, demonstrated significantly improved BCVA and similar final visual outcomes. Patients with worse presenting BCVA were more likely to undergo PPV or IVI whereas those with better presenting BCVA had excellent outcomes with observation alone. Improved BCVA was not associated with the number of IVIs or anticoagulant use.

show abstract

“…Treatment of posterior segment disorders often requires the administration of drugs over extended periods of time, which is usually achieved by injection of the drug as close to the diseased tissue as possible. For exudative age-related macular degeneration (AMD), choroidal neovascularization is controlled by monthly intravitreal injections of anti-VEGF (vascular endothelial growth factor) throughout the life of the patient, with substantial risk of side effects including endophthalmitis and ocular hypertension [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Biocompatibility of Poly(ester amide) (PEA) Microfibrils in Ocular Tissues

et al. 2014

View full text Add to dashboard Cite

Drug delivery systems (DDS) are able to deliver, over long periods of time, therapeutic concentrations of drugs requiring frequent administration. Two classes of DDS are available, biodegradable and non-biodegradable. The larger non-biodegradable implants ensure long-term delivery, but require surgical interventions. Biodegradable biomaterials are smaller, injectable implants, but degrade hydrolytically and release drugs in non-zero order kinetics, which is inefficient for long-term sustained drug release. Biodegradable poly(ester amides) (PEAs) may overcome these difficulties. To assess their ocular biocompatibility and long-term behavior, PEA fibrils were analyzed in vitro and in vivo. In vitro, incubation in vitreous humor changes to PEA structure, suggests degradation by surface erosion, enabling drug release with zero order kinetics. Clinical and histological analysis of PEA fibrils implanted subconjunctivally and intravitreally showed

show abstract

Hématomes maculaires après injections intravitréennes d’anti-VEGF pour dégénérescence maculaire liée à l’âge : série rétrospective

Cited by 15 publications

References 23 publications

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD

Clinical Outcomes of Retinal Arterial Macroaneurysms With Vitreous Hemorrhage Treated With Observation, Antivascular Endothelial Growth Factor Intravitreal Injections, or Pars Plana Vitrectomy

Biocompatibility of Poly(ester amide) (PEA) Microfibrils in Ocular Tissues

Contact Info

Product

Resources

About